Adipocytokines provide the circuitry by which adipose tissue communicates among its component cells which include adipocytes, stromal cells, immune cells and vascular elements, with adipose tissue depots in other locations throughout the body and with other tissues in order to regulate physiologic processes of energy intake, utilization, and distribution. Since disturbances, both qualitative and quantitative, in adipocytokine function contribute significantly to many of the comorbidities associated with obesity, including diabetes, cardiovascular disease and cancer, this volume, which discusses most of the major adipocytokines independently and collectively and their roles in normal and pathologic processes, should be useful to all individuals seeking a deeper understanding of these processes. Moreover, it provides a valuable complement to the series on Energy Balance and Cancer, in which each volume is focused on a specific aspect of this process, which now constitutes an expanding problem as the obesity pandemic continues and more of the population reaches the age where cancer is most prevalent. This volume should provide a valuable resource to all clinicians and scientists engaged in caring for susceptible patients and in exploring the relation between energy balance and cancer as well as an important platform to providing the background for research development.

Cell Press Reviews: Cancer Therapeutics informs, inspires, and connects cancer researchers at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publicatio offers a broad view of some of the most compelling topics in cancer therapeutics including: Genetic approaches for personal oncologyTargeting epigenetic dysregulation and protein interaction networksVaccines and antibodies in cancer immunotherapyTumor heterogeneity and chemotherapy resistanceTumor associated macrophages in anticancer treatment

Contributions come from leading voices in the field, including: - Daniel A. Haber, Director of Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School - Tony Kouzarides, Professor at the University of Cambridge, Deputy Director of the Wellcome Trust/Cancer Research UK Gurdon Institute, and a founder of the cancer drug discovery company Chroma Therapeutics - Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, President of the American Association for Cancer Research, member of the presidentially appointed National Cancer Advisory Board, and recipient of the 2013 Breakthrough Prize in Life Sciences

Cell Press Reviews: Cancer Therapeutics is part of the Cell Press Reviewsseries, which features reviews published in "Cell Press" primary research and "Trends" reviews journals.
Provides timely, comprehensive articles on a wide range of topics in cancer therapeutics
Offers insight from experts on genetic, molecular, and cellular aspects of cancer therapy
Features reviews on basic science advances translated into drug discovery and therapeutic approaches
Includes articles originally published in "Cell, Cancer Cell, Trends in Genetics, Trends in Molecular Medicine," and "Trends in Pharmacological Sciences""

Lynch syndrome (LS) is the most common cause of inherited colorectal cancer, a disease with a high mortality rate. An estimated 37,000 of diagnosed colorectal cancer cases worldwide are attributed to Lynch syndrome each year. Intensive cancer screening, with early initiation and frequent follow-up, can reduce colorectal cancer incidence and mortality in LS patients. This book provides an up-to-date overview on the genetic and epigenetic basis of Lynch syndrome. It evaluates clinical features of the disease and critically comments on molecular tools available for identifying mutations responsible for Lynch syndrome; in addition the importance of functional assays that can help clarify the clinical nature of identified mutations is also discussed. The book also focuses on challenges in genetic counselling of at-risk individuals and discusses related ethical issues. The purpose of the book is to give a concise knowledge base for the broader scientific and medical community, including genetic counselors, in order to improve awareness on the potential impact that the diagnosis of LS has on treatment, management and surveillance of LS patients.

"Cancer: Oxidative Stress and Dietary Antioxidants" bridges the trans-disciplinary divide and covers in a single volume the science of oxidative stress in cancer and then the potentially therapeutic usage of natural antioxidants in the diet or food matrix. The processes within the science of oxidative stress are described in concert with other processes such as apoptosis, cell signaling, and receptor mediated responses. This approach recognizes that diseases are often multifactorial and that oxidative stress is a single component of this.

Oncologists, cancer researchers, and nutritionists are separated by divergent skills and professional disciplines that need to be bridged in order to advance preventative as well as treatment strategies. While oncologists and cancer researchers may study the underlying pathogenesis of cancer, they are less likely to be conversant in the science of nutrition and dietetics. On the other hand, nutritionists and dietitians are less conversant with the detailed clinical background and science of oncology. This book addresses this gap and brings each of these disciplines to bear on the processes inherent in the oxidative stress of cancer.
Nutritionists can apply information related to mitochondrial oxidative stress in one disease to diet-related strategies in another unrelated disease Dietitians can prescribe new foods or diets containing anti-oxidants for conditions resistant to conventional pharmacological treatments Dietitians, after learning about the basic biology of oxidative stress, will be able to suggest new treatments to their multidisciplinary teamsNutritionists and dietitians will gain an understanding of cell signaling, and be able to suggest new preventative or therapeutic strategies with anti-oxidant rich foods

Cell Press Reviews: Stem Cells to Model and Treat Disease informs, inspires, and connects stem cell researchers and clinicians at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publication offers a broad view of some of the most compelling topics in stem cell research including: Safety and efficacy of stem cell treatmentsStem-cell-based organ regenerationIntegrating stem cells into personalized drug discoveryUsing pluripotent stem cells for treating neurological diseaseEngineering hematopoietic stem cells for innovative therapies

Contributions come from leading voices in the field, including: - Shinya Yamanaka, Recipient of the 2012 Nobel Prize for Physiology or Medicine, Recipient of the 2012 Millennium Technology Prize, Professor and Director of the Center for iPS Cell Research and Application at Kyoto University, Senior Investigator at the Gladstone Institute of Cardiovascular Disease, L.K. Whittier Foundation Investigator in Stem Cell Biology and Professor at the University of California, San Francisco - George Q. Daley, Samuel E. Lux IV Professor of Hematology/Oncology at Harvard Medical School and Director for the Stem Cell Transplantation Program at Boston Children s Hospital - Irving Weissman, Member of National Academy of Sciences, Virgina & D.K Ludwig Professor for Clinical Investigation in Cancer Research, and Director for Institute of Stem Cell Biology and Regenerative Medicine at Stanford University of Medicine

Cell Press Reviews: Stem Cells to Model and Treat Disease is part of the Cell Press Reviewsseries, which features reviews published in "Cell Press" primary research and "Trends" reviews journals.
Provides timely overviews on a wide range of stem cell applications
Offers insight from experts on the key opportunities and challenges facing the field
Features reviews on genetic, cellular, and molecular aspects of stem-cell-based applications
Includes articles originally published in "Cell, Cell Stem Cell, Neuron, Trends in Molecular Medicine," and "Trends in Biotechnology
""

This issue of Surgical Oncology Clinics of North America is devoted to the treatment of Colorectal Cancer. Editors Nancy Baxter, MD and Marcus Burnstein, MD have assembled some of the top experts in the field to review this important topic.Articles in this issue include: Colonoscopy: What are we missing?; Imaging in rectal cancer: MRI vs. ERUS; Local Excision for Rectal Cancer; Controversies in Neo-adjuvant treatment for rectal cancer; Management of the complete response; Controversies in laparoscopy for CRC; Colon resection - is standard technique adequate?; Quality Assurance in CRC surgery; Controversies in Abdomino-perineal resection; Functional Consequences of CRC management; Timing of adjuvant therapy for CRC; and Management of Stage IV disease.

2015 BMA Medical Book Awards Highly Commended in Oncology Category! The Molecular Basis of Cancer arms you with the latest knowledge and cutting-edge advances in the battle against cancer. This thoroughly revised, comprehensive oncology reference explores the scientific basis for our current understanding of malignant transformation and the pathogenesis and treatment of this disease. A team of leading experts thoroughly explains the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical trials and practice. Detailed descriptions of topics from molecular abnormalities in common cancers to new approaches for cancer therapy equip you to understand and apply the complexities of ongoing research in everyday clinical application. Effectively determine the course of malignancy and design appropriate treatment protocols by understanding the scientific underpinnings of cancer. Visually grasp and retain difficult concepts easily thanks to a user-friendly format with abundant full-color figures. Find critical information quickly with chapters following a logical sequence that moves from pathogenesis to therapy. Stay current with the latest discoveries in molecular and genomic research. Sweeping revisions throughout include eight brand-new chapters on: Tumor Suppressor Genes; Inflammation and Cancer; Cancer Systems Biology: The Future; Biomarkers Assessing Risk of Cancer; Understanding and Using Information About Cancer Genomes; The Technology of Analyzing Nucleic Acids in Cancer; Molecular Abnormalities in Kidney Cancer; and Molecular Pathology. Access the entire text and illustrations online, fully searchable, at Expert Consult.

PSA screening remains highly controversial due to several important disadvantages. More PSA is produced with prostatic enlargement and in other benign conditions such as urinary tract infections. False positive tests can then lead to unnecessary diagnostic workup with invasive prostate biopsy. Another major problem with screening programs in general is overdiagnosis of cancers that would not have caused harm during the patient's lifetime. For example, many prostate cancers have a relatively indolent behavior so may not require diagnosis or treatment in a patient with limited life expectancy. All forms of prostate cancer treatment have potential urinary and sexual side effects, so reducing overdiagnosis and overtreatment are critical public health issues. Because screening has many proven benefits but also significant harms, there are widely disparate guidelines on prostate cancer screening from major organizations worldwide. This issue of the Urologic Clinics will provide insights into the many different prostate cancer guidelines and related policy issues.

Molecular pathology is based on the emergence of new techniques that greatly enhance the diagnostic accuracy when facing with challenging differential diagnoses. In addition, new molecular techniques are entering the clinical arena for their value in predicting therapy response and tumor prognosis. This book provides a guide for the practicing pathologist and for both pathology residents and fellows during the daily sign-out of challenging cases. The book is organized by anatomical systems and provides a detailed description of molecular tests that may help in the diagnosis. Furthermore, a description of the current molecular tests required to identify patients for treatment is offered. The application of molecular pathology techniques to the clinical practice has already shown its usefulness and the number of such tests is growing exponentially as more molecular targets are discovered. Molecular Pathology and Diagnostics of Cancer will give practicing and training pathologists an up-to date resource to guide the correct management of pathology cases requiring molecular testing.

Gene therapy as a treatment for cancer is at a critical point in its evolution. Exciting new developments in gene targeting and vector technology, coupled with results from the first generation of preclinical and clinical studies have led to the design and testing of new therapeutic approaches. The Third Edition of "Gene Therapy of Cancer" provides crucial updates on the basic and applied sciences of gene therapy. It offers a comprehensive assessment of the field including the areas of suicide gene therapy, oncogene and suppressor gene targeting, immunotherapy, drug resistance gene therapy, and the genetic modification of stem cells. Researchers at all levels of development, from basic laboratory investigators to clinical practitioners, will find this book to be instructive.

Cancer gene therapy, like cancer therapy in general, is evolving rapidly, testing new concepts, targets and pathways, evoking new technologies, and passing new regulatory hurdles. Its essence, however, has not changed: the hope and challenges of returning altered genes to normal, using targeted gene expression to alter the function of both tumor and microenvironment, and in some cases normal cells, and delivering functionally important genes to specific cell types to increase sensitivity to killing or to protect normal cells from cancer therapies.

In some instances, gene therapy for cancer forms a continuum from gene repair through the use of molecularly modified cells; the use of viral and non-viral vector based gene delivery to both tumor and tumor microenvironment; the use of viral and gene based vaccines; and development of new gene-based therapeutics. The unique mechanistically chosen vector platforms are at the heart of this technology because they allow for direct and selective cell death and transient to sustained delivery of vaccine molecules or molecules that affect the microenvironment, vasculature, or the immune response.
Explains the underlying cancer biology necessary for understanding proposed therapeutic approaches Presents in-depth description of targeting systems and treatment strategiesCovers the breadth of gene therapy approaches including immunotherapeutic, drug resistance, oncolytic viruses, as well as regulatory perspectives from both the NCI and FDA

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics. This volume covers AEG-1/MTDH/Lyric implicated in multiple human cancers.
Provides information on cancer researchOutstanding and original reviewsSuitable for researchers and students

This issue, focusing on Breast Cancer, includes topics such as: Radiation Therapy for DCIS, Axillary dissection, Pathology in the age of personalized breast cancer treatment:, Clinical implications for breast cancer subsets defined by molecular diagnostics, Management of CNS Metastases in Breast Cancer, Endocrine therapy for advanced breast cancer, Targeting the PI3K pathway in breast cancer, Treating the Older Breast Cancer Patient, Adjuvant chemotherapy in the age of targeted treatment, and Novel radiotherapy approaches for early breast cancer

First published in 1943, "Vitamins and Hormones" is the longest-running serial published by Academic Press. The Editorial Board now reflects expertise in the field of hormone action, vitamin action, X-ray crystal structure, physiology and enzyme mechanisms.

Under the capable and qualified editorial leadership of Dr. Gerald Litwack, "Vitamins and Hormones" continues to publish cutting-edge reviews of interest to endocrinologists, biochemists, nutritionists, pharmacologists, cell biologists and molecular biologists. Others interested in the structure and function of biologically active molecules like hormones and vitamins will, as always, turn to this series for comprehensive reviews by leading contributors to this and related disciplines.

This volume focuses on hormones and breast cancer.

Key features:

* Contributions from leading authorities * Informs and updates on all the latest developments in the field

This issue focuses on Sarcoma in areas such as: Gastrointestinal Stromal Tumors: Risk assessment and adjuvant therapy, Gastrointestinal Stromal Tumors: Management of metastatic disease and emerging therapies, Liposarcoma, Leiomyosarcoma, Update in treatment and targets in cartilage and bone tumors, Update in treatment and targets in Ewing sarcoma, Angiosarcoma and Epithelioid Hemangioendothelioma, Emerging therapies for sarcoma, and Treatment of localized sarcomas.

This issue of Hematology/Oncology Clinics is guest edited by Dr. A. Koneti Rao and focuses on Disorder of the Platelets. Article titles include: Mechanisms of Platelet Activation and Inhibition, Testing Platelet Function, Clinical Implications of Platelet Genomics and Proteomics, Congenital Thrombocytopenias, Immune Thrombocytopenias, Heparin Induced Thrombocytopenia, and Functional defects: Chronic granulomatous disease (CGD) and beyond

This unique book provides a retrospective analysis of the changes in survival outcomes at the University of Texas, M.D. Anderson Cancer Center over the past six decades. Since opening its doors in 1944, M.D. Anderson has kept a continuous, uninterrupted data repository of the treatment and outcomes of each of its patients. It is this visionary database from the center s tumor registry which makes this groundbreaking book possible. Tracking results across time, this book shows radical shifts in outcomes trends, where great progress has been made, and where there is still a long way to go, and offers a snapshot into the parallel history of developments in care. Such data is crucial to informing how patients are counseled, how treatment decisions are determined, and how prognoses are made.

"60 Years of Survival Outcomes at the University of Texas, M.D. Anderson Cancer Center" is the only book to concurrently present longitudinal data on survival outcomes across the spectrum of rare and common cancers. Each chapter deals with a specific disease site, discussing current management approaches and presenting key data replete with illustrative charts, graphs, and tables. With the resources available only to the practitioners at this inimitable institution, this book heralds a cornerstone moment in the study of survival outcomes and the depth of our knowledge of cancer care. "

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.

Cervical Cancer screening, which includes the PAP test and HPV testing is an essential part of a woman's routine healthcare. This issue of the Ob/Gyn Clinics covers colposcopy and screening for women at all stages of life, along with the HPV vaccine, treatment options, and what is on the horizon regarding ever-changing screening methods.

While cancers of the oral cavity and oropharynx were overwhelming found in smokers and drinkers, a dramatic shift is occurring with a dramatic rise in the incidence of HPV-associated oropharyngeal cancers while oral cavity cancers and HPV-negative oropharyngeal cancers appear to be declining in incidence, reflecting the reduction in cigarette smoking. These trends also have implications for how Otolaryngologists prevent, diagnose, workup, treat, and follow these patients. The focus of information in this issue is on oral cavity and oropharyngeal cancer and the implications of the HPV epidemic on this disease. Amongst the medical community during this period of trying to better grasp the association of HPV with oropharyngeal cancers, there are misconceptions and a lack of knowledge of these important shifts which are addressed by Guest Editors Jeffrey Myers and Erich Sturgis of the University of Texas, MD Anderson Cancer Center. Topics include: Epidemiology- Control of a tobacco epidemic? But emergence of a HPV epidemic?; Oral cavity and Oropharyngeal Cancer Genomics; Why Otolaryngologists need to be aware of Fanconi anemia; Impact on HPV on Orpharyngeal Cancer Biology and Response to Therapy-Implications for Treatment; Oral premalignancy- The roles of early detection and chemoprevention; Evaluation and staging- Limitations despite technological breakthroughs; 7) Surgical treatment innovations; Radiotherapy- The "Particle-rs? of energy, dose, and delivery method; Systemic Treatment- Its role before, during, and after definitive treatment; How to maximize functional assessment/rehabilitation; Standardizing treatment for Cancers - An approach to cancer care or crisis?; Survivorship in Oral Cancer- Competing mortalities, morbidities, and second malignancies.

This issue of Thoracic Surgery Clinics devoted to Therapy for Esophageal Cancer will be Guest Edited by Dr. Wayne Hofstetter. Articles in this issue include: Radiographic and Endoscopic staging of esophageal cancer; Endoscopic management of HGD/Early stage esophageal cancer; Induction chemotherapy for esophageal cancer; Personalizing therapy for esophageal cancer patients; Surgery for esophageal cancer: Goals of resection and optimizing outcomes (Lymph node dissection in esophageal cancer/R0 Resection); Standardizing Esophagectomy Complications; Adjuvant therapy (post-op) for esophageal cancer; Definitive CXRT for esophageal cancer; Salvage Esophagectomy in the management of recurrent or persistent esophageal cancer; and Quality of life after curative resection for esophageal cancer.

Leading researchers are specially invited to provide a complete understanding of a key topic within the multidisciplinary fields of physiology, biochemistry and pharmacology. In a form immediately useful to scientists, this periodical aims to filter, highlight and review the latest developments in these rapidly advancing fields.

This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.

While HIV-1 continues to be well-researched, this detailed volume draws attention to other members of the Retrovirus family, namely the Human T-lymphotropic Viruses (HTLVs), featuring the most updated technical information about HTLV determination and the methods to investigate their interaction with the host immune system and interfering pathogens. The contents include essential aspects of epidemiology and virus transmission, novel and robust methodologies for studying the effects of trans-activating regulatory HTLVs' proteins, the latest techniques for genotyping and gene expression analysis, as well as cellular phenotype and dynamics. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Human T-Lymphotropic Viruses: Methods and Protocols serves as an ideal guide to an area of study that is very much worthy of further research.

"Advances in Cancer Research" provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics.